The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI

To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either exon 19 deletion (E19del) or exon 21...

Full description

Saved in:
Bibliographic Details
Published in:International journal of general medicine 2018-01, Vol.11, p.423-430
Main Authors: Phan, Thang Thanh, Ho, Toan Trong, Nguyen, Hue Thi, Nguyen, Hang Thuy, Tran, Thu Bich, Nguyen, Son Truong
Format: Article
Language:English
Subjects:
Adenocarcinoma
Analysis
Biological markers
Blood
Cancer therapies
Care and treatment
Chemotherapy
Development and progression
EGFR TKI
Epidermal growth factor
Ethics
Hospitals
Laboratories
Lung cancer
Lymphocytes
Medical prognosis
Neutrophils
NLR
Non-small cell lung cancer
NSCLC
Original Research
Patients
Phenols (Class of compounds)
Prognosis
Small cell lung cancer
Studies
Tumors
Tyrosine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either exon 19 deletion (E19del) or exon 21 L858R substitution mutation (L858R) were selected for this study. The blood cell count at different stages of treatment was used to calculate the inflammatory markers. The Kaplan-Meier statistics and Cox regression model were used to test the differences of progression-free survival (PFS) between groups by the optimal cutoff point of biomarkers. The median values of white blood cell (WBC), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) in NSCLC patients tended to be reduced after 3 months treated with EGFR TKI and increased conversely when the disease develops progression (
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S174605